TP53 mutations frequently occur in head and neck squamous cell carcinoma (HNSCC) patients without human papillomavirus infection. The recurrence rate for these patients is distinctly high. It has been actively explored to identify agents that target TP53 mutations and restore wild-type (WT) TP53 activities in HNSCC. PRIMA-1 (p53-reactivation and induction of massive apoptosis-1) and its methylated analogue PRIMA-1 Met (also called APR-246) were found to be able to reestablish the DNA-binding activity of p53 mutants and reinstate the functions of WT p53. Herein we report that piperlongumine (PL), an alkaloid isolated from Piper longum L., synergizes with APR-246 to selectively induce apoptosis and autophagic cell death in HNSCC cells, whereas primary and immortalized mouse embryonic fibroblasts and spontaneously immortalized non-tumorigenic human skin keratinocytes (HaCat) are spared from the damage by the cotreatment. Interestingly, PL-sensitized HNSCC cells to APR-246 are TP53 mutation-independent. Instead, we demonstrated that glutathione S-transferase pi 1 (GSTP1), a GST family member that catalyzes the conjugation of GSH with electrophilic compounds to fulfill its detoxification function, is highly expressed in HNSCC tissues. Administration of PL and APR-246 significantly suppresses GSTP1 activity, resulting in the accumulation of ROS, depletion of GSH, elevation of GSSG, and DNA damage. Ectopic expression of GSTP1 or pre-treatment with antioxidant N-acetyl-L-cysteine (NAC) abrogates the ROS elevation and decreases DNA damage, apoptosis, and autophagic cell death prompted by PL/APR-246. In addition, administration of PL and APR-246 impedes UMSCC10A xenograft tumor growth in SCID mice. Taken together, our data suggest that HNSCC cells are selectively sensitive to the combination of PL and APR-246 due to a remarkably synergistic effect of the co-treatment in the induction of ROS by suppression of GSTP1.
Introduction
Normal cells physiologically retain redox homeostasis by balancing the generation and elimination of reactive oxygen species (ROS). The redox dynamics fluctuate within a tolerable range. Due to the increased proliferation and disturbed metabolism, cancer cells, however, possess a high level of ROS. When the increase of ROS reaches a critical level (the threshold), it may potentially overwhelm the cellular antioxidant capacity and trigger the cell death [1] . This common effect suggests that cancer cells may be more vulnerable to oxidant stress. Indeed, applications of small molecules that increase ROS accumulation have been proposed for cancer therapy [2] [3] [4] [5] [6] [7] [8] [9] [10] .
Piperlongumine (PL) is an alkaloid originally identified in Piper longum L. PL bears multiple functions on antiplatelet aggregation, anti-inflammatory, and anti-cancer [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Raj et al. [15] screened several thousand biologically active compounds and found that PL is the strongest activator to promote p53-mediated transcription. The antitumor effect of PL was much more dramatic than that of cisplatin in a melanoma allografted mouse model [14] . In a spontaneous mouse mammary tumorigenesis model, PL outperformed paclitaxel [15] . Gutathione-Stransferase-P1 (GSTP1) and carbonyl reductase 1 (CBR1), two enzymes participating in cellular response to oxidative stress, were among the most enriched proteins after PL exposure, indicating the possible involvement of ROS in the process. Indeed, the authors demonstrated that treatment of PL augmented the levels of ROS in cancer cells but not in non-transformed cells [15, 16] . PRIMA-1 (p53-reactivation and induction of massive apoptosis-1) and PRIMA-1 Met (methylated analogue of PRIMA-1, also called APR-246) are quinuclidine compounds, which can restore the DNA-binding activity of p53 mutants and reinstate the functions of wild-type (WT) p53 [26] [27] [28] . PRIMA-1 and APR-246 are converted to methylene quinuclidinone (MQ), a Michael acceptor in the cell. MQ binds covalently to cysteines in mutant p53 and unfold WT p53, hence reestablishing the action of p53 [28] [29] [30] . Consequently, p53 target genes, such as PUMA, NOXA, and BAX, are up-regulated and caspases −2, −3, and −9 are activated by PRIMA-1 or APR-246 [28] . Recent studies showed that MQ may also possess p53-independent functions in the induction of cell death in a variety of tumor types [31] . MQ modifies and converts antioxidant thioredoxin reductase 1 (TrxR1) into pro-oxidant NADPH oxidase, promoting the generation of ROS [32] [33] [34] . In addition, APR-246 also decreases intracellular content of glutathione (GSH), hence enhancing the accumulation of ROS [35] .
In the current study, we investigated the synergistic effect of PL and APR-246 in the induction of cell death in head and neck squamous cell carcinoma (HNSCC), in which mutations of TP53 are frequently identified and relevant to tumor progression and recurrence [36] [37] [38] . The combination is based on the strong induction of ROS by both agents, which may create a reciprocal sensitization. In addition, reactivation of p53 by APR-246 may provide a mechanistic basis for the action of PL [15] . Our results support the premise and suggest that co-treatment of PL and APR-246 synergistically induces apoptosis and autophagical cell death in HNSCC cells.
Results

PL enhances APR-246-mediated cell death in HNSCC cells
To determine whether PL possesses a synergistic effect with TP53 reactivator, we exposed UMSCC10A and FaDu, two HNSCC cell lines with TP53 mutation to PL and/or APR-246. As shown in Fig. 1a-d , both PL and APR-246 individually suppressed cell survival and bore a modest effect on the killing of HNSCC cells. Co-treatment with PL and APR-246 led to a marked reduction in cell viability and an increase in cell death ( Fig. 1a-d ). Similar results were acquired for UMSCC1 and UMSCC17A cell lines (see Fig.  2 ).
To further evaluate the synergistic effect of the cotreatment, we exposed UMSCC10A cells to PL and/or APR-246 and assessed cell growth using the clonogenic survival assay. As shown in Fig. 1e , colony formation was suppressed with the treatment of PL or APR-246 and the effect was strikingly enhanced with the co-treatment. Fraction affected (FA) levels from growth inhibition percentages were markedly higher in co-treatment groups as compared with those treated with PL or APR-246 alone ( Fig. 1f ). Combination index (CI), a quantitative representation for the degree of drug interaction and an indicator for drug synergy, was calculated over a range of FA levels from growth inhibition percentages [39] . A CI < 1.0 can be considered as synergy [40] . As shown in Fig. 1g , the CI plots in the co-treated cells revealed a strongly synergistic effect when FA values were 50% or greater ( Fig. 1g , Supplementary Figure 1 ). These results suggest that PL and APR-246 possess a synergistic effect against HNSCC cells.
PL and/or APR-246 have a marginal impact on the survival of non-transformed cells
To determine whether the combined effect of PL and APR-246 was uniquely to cancer cells (HNSCC), we exposed the primary and immortalized mouse embryonic fibroblasts (MEFs) to the co-treatment. It showed that there was only marginal reduction in cell viability ( Supplementary Figures  2a and b ). Consistently, we detected only a minimal decrease in cell viability in spontaneously immortalized non-tumorigenic human skin keratinocytes (HaCat) (Supplementary Figure 2c ). These results indicate that PL and APR-246 only have a limited impact on the survival of nontransformed cells.
PL and APR-246 prompt both apoptosis and autophagic cell death
To characterize the cell death enhanced by PL in APR-246treated cells, we assessed apoptosis and autophagy in UMSCC10A cells with the co-treatment. As shown in Fig.  2a , b, administration of PL or APR-246 induced the activation of parp-1, caspase-7, and caspase-9, which was markedly enhanced by the combination of the two agents. DNA fragments released from the nuclei in the treated cells were remarkably increased, supporting the existence of ) and UMSCC17A (wild-type TP53) cells (c, d) were exposed to 10 µM PL and 25 µM APR-246 for 72 h. After the treatment, cell death and cell viability were determined as described in Fig. 1 . e-g UMSCC1 cells were infected with lentiviruses expressing TP53 mutants R175H, R249S, R273H, R280K, and wild-type TP53, or GFP (control). Cell transduction efficiency was about 60% with the fluorescence microscopy analysis at 48 h after the infection. Immunoblot was used for the detection of p53 expression in the transduced cells (e). Cell death (f) and cell viability (g) in the cells treated with 10 µM PL and 25 µM APR-246 for additional 72 h were determined as described in Fig. 1 . The data represent the mean ± S.D. *P < 0.01, n = 3 apoptosis ( Fig. 2a, b ). Interestingly, immunoblot detection also revealed that under the treatment of PL-and/or APR-246, a significant part of light chain 3 (LC-3, also known as autophagy-related gene 8, ATG8) were converted from isoform I (LC3-I) to isoform II (LC3-II), indicating the induction of autophagy ( Fig. 2a ). To visualize autophagy, we established UMSCC10A/green fluorescent protein (GFP)-LC3 cells, a stable cell line that expresses GFPtagged LC3 [13] . GFP-LC3 formed cytoplasmic puncta in cells treated with PL and/or APR-246 but not in control cells (Fig. 2c ), supporting the notion that co-treatment of PL and APR-246 leads to both apoptosis and autophagy.
To validate the contribution of apoptosis in PL and APR-246-induced cell death, we pre-treated UMSCC10A cells with pan-apoptotic inhibitor benzyloxycarbonylvalylalanyl-aspartic acid (O-methyl)-fluoro-methylketone (z-VAD-fmk) before PL and/or APR-246 were added. As expected, PL and APR-246-induced DNA fragment was markedly reduced (Fig. 2b ). Consistently, cell death was decreased and the cell viability was improved by the pretreatment with z-VAD-fmk ( Fig. 2d, e ). However, cells pretreated with z-VAD-fmk still underwent a certain level of cell death and the cell viability was not completely recovered when PL/APR-246 was added ( Fig. 2d, e ). In addition, although PL or APR-246 alone induced a notable cell death ( Fig. 1) , PARP cleavage and activation of caspases were relatively low ( Fig. 2a ). Collectively, these results support the notion that additional cell death (autophagic cell death) may also be involved.
To determine the impact of autophagy on PL and APR-246-induced cell death, we pre-treated UMSCC10A cells with an autophagy inhibitor 3-methyladenine (3-MA) [13] , which blocks class III PI3Ks that are critical during the late stage of vesicle expansion, and analyzed autophagy formation after the addition of PL and APR-246. As shown in in PL/APR-246-treated cells. More importantly, pretreatment with 3-MA reduced cell death and improved cell viability resulted from the co-treatment of PL and APR-246 although both were not completely reversed (Fig. 2d,  e ), indicating the participation of autophagy in the cell death induced by the PL/APR-246. Consistent with these observations, pre-treatment with both z-VAD-fmk and 3-MA strikingly reduced the cell death and further improved cellular viability in the PL/APR-246-co-treated cells (Fig. 2d,  e ), supporting our notion that PL and APR-246 induce apoptosis and autophagy, both of which contribute to the cell death in the co-treatment.
PL-induced sensitization of HNSCC cells to APR-246 is independent of TP53
PRIMA-1 and APR-246 were originally developed as mutant p53 re-activators [20, 25] . However, recent studies revealed that a range of functions that the family compounds have may be independent of p53 mutation [28] [29] [30] .
To define whether the cell death resulted from the cotreatment of PL and APR-246 is relevant to p53 status, we detected cell viability and cell death in UMSCC17A (WT p53) and UMSCC1 (p53 deficient) cells with the cotreatment. Similar to the responses of p53 mutated UMSCC10A and FaDu cells in Fig. 1a-d , both UMSCC1 and UMSCC17A cells reacted to the co-treatment and shared a similar pattern that cellular viability was reduced and cell death was elevated by the co-treatment ( Fig. 3a-d) .
To further assess the involvement of p53 in PL-and APR-246-induced cell death, we transfected WT and mutant p53 vectors into UMSCC1 cells (Fig. 3e) . Consistently, a similar response to the co-treatment was observed in cells with WT and mutant p53 ( Fig. 3f, g) . Collectively, our data suggest that PL-enhanced sensitivity of HNSCC cells to APR-246 is independent of TP53.
Co-treatment of PL and APR-246 leads to the accumulation of ROS in HNSCC cells
We and other groups previously reported that PL treatment leads to an increase in ROS levels and induces cell death in a variety of cells [13] [14] [15] [16] . Interestingly, APR-246 is also able to induce ROS by disturbing the cellular redox balance [32] [33] [34] [35] . Thus, application of PL and APR-246 may synergistically elevate intracellular ROS, rendering cancer cells a severe oxidant stress. To test this hypothesis, we detected intracellular ROS levels in PL-and APR-246treated UMSCC10A cells. We found that application of PL and/or APR-246 individually or together markedly increased intracellular ROS contents (Fig. 4a ). However, PL and/or APR-246 only marginally increased ROS levels in non-transformed MEFs (Fig. 4b) . Consistent with increased ROS in the cells, treatment with PL and/or APR-246 decreased the GSH and increased the oxidized glutathione (GSSG) levels in UMSCC10A cells (Fig. 4c, d) . Moreover, pre-treatment with the reducing agent 5 mM NAC, which quenches ROS, prevented the co-treatment-induced ROS accumulation, GSH depletion, and GSSG increase in UMSCC10A cells (Fig. 4a, c, d) . Taken together, our results suggest that PL exposure promotes the accumulation of ROS in APR-246-treated cells.
Treatment with PL and APR-246 induces DNA damage
A direct outcome of elevated intracellular ROS is DNA damage, which may eventually result in genomic instability and cell death. The DNA adduct, 8-oxo-7, 8-dihydro-20deoxyguanine (8-oxo-dG) is formed by the reaction of OH radical with the DNA guanine base, leading to oxidative DNA damage [41] . To determine whether PL and APR-246-prompted ROS accumulation is able to cause oxidative DNA damage, we exposed UMSCC10A cells to PL and/or APR-246 and measured 8-oxo-dG. As shown in Fig. 5a , both PL and APR-246 exposures led to a high level of 8oxo-dG, in particular under the treatment of combination.
To further identify the DNA damage in PL and APR-246treated cells, we exposed UMSCC10A cells to both agents and detected the formation and repair of DNA damage by the comet assay [41] . The tail moment that reflects the frequency of DNA breaks was measured to quantify DNA damage. In both PL-and APR-246-treated cells, levels of DNA damage were noticeably higher than those in control (PBS)-treated cells (Fig. 5b, c) . When both agents were used for the co-treatment, damaged DNAs in the tail moment in cells were strikingly elevated (Fig. 5b, c) . Phosphorylation of histone H2AX (γ-H2AX) occurs at DNA breakage sites and is another DNA damage marker [41] . We found that γ-H2AX was increased in PL-or APR-246-treated cells and elevated by the co-treatment both in the immunofluorescence assay and in the immunoblot analysis ( Fig. 5d, e ). Taken together, our results suggest that treatment with PL and APR-246 not only elevates the level of intracellular ROS but also induces DNA damage in HNSCC cells.
GSTP1 mediates the activity of PL and APR-246 in HNSCC cells
PL treatment selectively increased ROS levels (Fig. 4a Knockdown of GSTP1 increases intracellular ROS levels, but only marginally escalates ROS in PL-and APR-246-treated cells. Scramble shRNA and shR-GSTP1 were packaged with lentiviral system and transduced into UMSCC10A cells. After selection with puromycin for 2 weeks, the cells were verified for the knockdown by western blot (g). The cells were then exposed to 10 µM PL and/or 25 µM APR-246 for 72 h for intracellular ROS determination (h) or cell death detection (i). ROS were measured as described in Fig. 4 . Cell death was determined as described in Fig. 1b, d . Means ± S.D. for three independent experiments were presented. *P < 0.01 activity in cancer cells, in particular GSTP1 that was the highest-confidence hit in a recent screening assay to identify targets and their associated complexes that bind to PL [15, 41] . To determine whether GSTP1 also plays a role in APR-246-induced ROS accumulation, in particular in PL-and APR-246 co-treatment-induced oxidative stress and cell death, we detected the expression of GSTP1 with immunoblot in UMSCC10A cells with the co-treatment. Surprisingly, neither PL nor APR-246 affected the protein level of GSTP1 (Fig. 6a ). We next measured the activity of GSTP1 in PL-and/or APR-246-treated cells. It showed that PL and/or APR-246 inhibited the activity of GSTP1, in particular under the co-treatment ( Fig. 6b and Supplementary Figure 3 ). Application of antioxidant NAC partially recovered the activity of GSTP1 ( Supplementary Figure 4) . Further, stably overexpressing GSTP1 markedly reduced PL-and APR-246-induced ROS elevation, autophagy induction, and cell death ( Fig. 6c-f ). In a complementary study, knockdown of GSTP1 marginally increased the levels of ROS in PL-and APR-246-treated cells and almost bore no influence on autophagy induction and cell death occurred in PL/APR-246 treatment (Fig. 6f-i ), suggesting GSTP1 is highly expressed in HNSCC tissues. Application of PL and APR-246 reduces xenograft tumor growth of HNSCC cells. a, b 5 × 10 6 UMSCC10A cells were inoculated subcutaneously under the flank of SCID mice. Three days later, the mice were randomized into four groups (n = 10/group) receiving PBS (control), PL (4 mg/kg/day), APR-246 (100 mg/kg/day), or PL (4 mg/kg/day)+APR-246 (100 mg/ kg/day) by i. p. Treatment was performed daily for 24 days. a Tumor volumes were measured every 3 days. *P < 0.01 as compared with control treatment group. (b) The tumors were removed from euthanized mice. IHC was used to detect GSTP1. Scale bar = 100 µm. c-e HNSCC tissues from healthy (n = 28) and HNSCC (n = 194) subjects were assessed for the expression of GSTP1 by IHC. c Representative IHC staining of GSTP1 in a normal head and neck epithelial tissue and in an HNSCC tissue. Scale bar = 100 μm. d Quantification of GSTP1 expression in human head and neck tissues. Low: overall negative or weak staining; high: overall moderate or strong staining. The Pearson's chi-square test was used to analyze the distribution difference of GSTP1 between healthy and HNSCC tissues (P < 0.01). e H-scores of GSTP1 in head and neck tissues (*P < 0.01) that other relevant antioxidant targets may also be regulated by the agents or that there might have partially overlapping functions between GSTP1 knockdown and the co-treatment in the cell. Taken together, these data support the notion that PL-and/or APR-246 induce cell death by interfering with redox and ROS homeostatic regulators such as GSTP1.
Application of PL and APR-246 reduces xenograft tumor growth of HNSCC cells
To validate the role of PL and APR-246 in the suppression of HNSCC cells, we subcutaneously inoculated UMSCC10A cells into SCID mice. Application of PL or APR-246 alone reduced tumor volumes (P < 0.01), whereas co-treatment with the two agents substantially increased the suppressive effect and led to marked reductions in tumor volumes ( Fig. 7a) . Consistent with the observation that the expression of GSTP1 was not affected by PL/APR-246 ( Fig. 6a ), treatments with these agents bore no impact on the level of GSTP1 by the immunohistochemistry staining ( Fig.  7b ).
GSTP1 is highly expressed in HNSCC tissues
To investigate the pathological significance of GSTP1 in HNSCC, we assessed its expression in human HNSCC tissues using IHC. Tissues from normal (n = 28) and HNSCC (n = 194) were analyzed. Healthy head and neck epithelial tissues or normal tissues adjacent to cancer generally displayed weak GSTP1 signals (Fig. 7c) . In contrast, some 70% HNSCC cases were positive for GSTP1 ( Fig. 7c,  d) . The H score [42] also demonstrated an intense signal of GSTP1 in cancerous tissues (Fig. 7e ). Taken together, these data are consistent with our in vitro observation that GSTP1 levels are elevated in HNSCC cells and it may be worthy exploring it as a potential target for precision therapy of HNSCC as we demonstrated in this study.
Discussion
In this study, we found that combination of PL and APR-246 resulted in a marked increase of cell death in various HNSCC cell lines, including FaDu, UMSCC1, UMSCC10A, and UMSCC17A. Further, we showed that the cytotoxicity of PL and APR-246 was selective to malignant cells, but not to non-transformed cells. The different responses of malignant cells and non-transformed cells to the combination of PL and APR-246 may provide a therapeutic window for effectively targeting cancer cells with limited off-target effects.
It sounds rationale to postulate that the combination might work specifically on TP53-mutated cells since APR-246 was originally developed for targeting TP53 mutation and restored the activity of p53 in the cells [20, 25] . To our surprise, UMSCC1 (TP53 deficient), UMSCC17A (wildtype TP53), and FaDu and UMSCC10A (TP53 mutation) cells were responsive to PL and APR-246 similarly (Figs. 1a-d and 3a-d). More importantly, we transfected various mutant and wild-type TP53 constructs into TP53-null UMSCC1 cells, and the transduction did not improve or reduce the response of the cells to the combined treatment of APR-246 and PL, further suggesting the independence of TP53 for the function we observed in the co-treated cells. These results are consistent with recently reports showing that APR-246 and its analogue PRIMA-1 possess TP53 independent effect on the killing of tumor cells [28] [29] [30] .
We and other groups previously reported that PL treatment increases intracellular ROS and hence induces cell death [13] [14] [15] [16] . Interestingly, APR-246 is also able to induce ROS by disturbing the cellular redox balance [28] [29] [30] . Thus, application of PL and APR-246 may synergistically elevate intracellular ROS, rendering cancer cells a severe oxidant stress. Our results supported this hypothesis and demonstrated that combination of PL and APR-246 led to a strikingly elevation of ROS in cancer cells, but not in nontransformed MEFs (Fig. 4) , providing a concrete evidence for the selectivity of the co-treatment against cancer cells. Unlike normal cells that keep redox homeostasis by balancing the production and removal of ROS and the redox dynamics fluctuates in a tolerable range, cancer cells possess high levels of ROS due to active cell metabolism and the hypoxia [43, 44] . Therefore, agents that increase ROS generation or decrease ROS clearance may push the level of ROS in the tumor over the threshold of life and death to prompt cell death [1] .
Previous reports demonstrated that PL interacts with and suppresses the activity of GSTP1, CBR1, and TrxR1 in cancer cells. GSTP1 was the highest-confidence hit in a recent screening assay to identify targets and their associated complexes that bind to PL [15, [45] [46] [47] . In keeping with these findings, we found that around 70% HNSCC tissues bore a high level of GSTP1 expression whereas only about 14% normal tissues possessed elevated GSTP1 ( Fig.  7c-e ). Overexpression of GSTP1 mitigated ROS accumulation and prevented PL/APR-246-induced cell death to a certain level, indicating that GSTP1 may play a critical role in the action of the co-treatment [48, 49] . On the other hand, how, depletion of GSTP1 with shRNA increased the ROS, but could not reach that in PL-/APR-246 treated cells ( Fig.  6c-i ), suggesting that additional ROS-relevant enzymes, such as TrxR1 and CBR1, may also participate in the oxidant stress in the co-treatment. It is interesting to clarify the contribution of these enzymes to the ROS in PL/APR-246 co-treatment in the future.
Taken together, we identified that combination of PL and APR-246 selectively induces HNSCC cell death by inactivating GSTP1 and hence elevating intracellular ROS levels. Complementary to the in vitro findings, our in vivo investigation provides further evidence demonstrating that cotreatment with PL and APR-246 could be a valuable means for controlling HNACC tumor growth. Due to the selectivity and high efficiency, combination of the two compounds for the treatment of HNSCC may possess a great feasibility and bear a high potential.
Materials and methods
Cell lines, primary MEFs, and drug treatment FaDu and HaCat were from ATCC (Manassas, VA). UMSCC1, UMSCC10A, and UMSCC17A were kindly provided by Dr. Thomas Carey's lab in the University of Michigan [50] . MEFs were isolated from C57BL6 mice and immortalized by culturing and overcoming the crisis stage at passage 11-16 [41] . Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Atlanta Biologicals, Atlanta, GA). PL, APR-246, NAC, and 3-MA were ordered from Sigma-Aldrich (St. Louis, MO). z-VAD-fmk was from Biomol International (Plymouth Meeting, PA).
Plasmids and transfection
WT and mutation p53 plasmids (R175H, R249S, R273H, and R280K) were reported previously [51, 52] and recloned into pEF1a lentiviral vector and packaged with 293 T cells. Lentiviruses expressing WT and mutant p53 were used for the infection of UMSCC1 cells, followed by selection with puromycin. shRNA-control and shRNA-GSTP1 were purchased from Thermo Scientific (Lafayette, CO), packaged with lentiviral expression system, and applied for the transduction.
Assays for cell survival and death
Cell viability was determined using the MTT assay [41] . Cell death was detected with trypan blue exclusion assay. Apoptosis in cells exposed to different treatments was measured with a kit from Roche Diagnostics quantifying nucleosome enrichment in cytoplasm.
Clonogenic survival assay and analysis of combined drug effects
Three thousand UMSCC10A cells each well were planted in a six-well plate and treated concurrently with different dosages of PL and APR-246. Sixteeen hours later, the reagents were removed by washing the cells with 1 × PBS for three times. The cells were cultured for 14 days before fixation for clonogenic determination. Colonies with 50 or more cells were calculated. Survival rate of cells in each treatment was the ratio of value to control group. FA was calculated by "1−survival rate". CI was calculated with the CompuSyn software (ComboSyn, Inc., Paramus, NJ, 2007) [39] . A CI <1.0 was considered as synergy [40] .
Antibody and immunoblot
Whole-cell extracts in RIPA buffer with proteasome inhibitors were isolated for SDS-PAGE and used for the western blot analysis. Anti-p53, caspase-7, and caspase-9 antibodies were ordered from BD Pharmingen (San Diego, CA). Antibodies against total and phosphorylated H2AX, p21, and GAPDH were purchased from Abcam Inc. (Cambridge, MA). Antibodies against PARP and GSTP1 were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-LC3 polyclonal antibody was ordered from Novus Biological Inc. (Littleton, CO).
Analysis with a fluorescent microscope UMSCC10A cells were transduced with pcDNA3/GFP-LC3 for 24 h and exposed to PL and/or APR-246 in the presence or absence of 3-MA [13, 53] . Autophagy was determined by calculating GFP-LC3 dots (autophagosomes/ autolysosomes) with the Olympus IX51 fluorescence microscope (Center Valley, PA, USA).
Measurement of ROS
About 100 ng/ml dihydroethidium (DHE) was added to cell culture medium at 1 h before the cells were trypsinized and collected. Cells were then washed with 1 × PBS for three times and analyzed by flow cytometry [41] .
Measurement of GSH, GSSG, and GSTP1
Clarified supernatants from lysates of 2 × 10 5 cells were isolated for the measurement of GST enzymatic activity, GSH, and GSSG. GST enzymatic activity was determined with a GST Activity Assay Kit from Abcam (ab65326). GSH and GSSG were measured with a GSH/GSSG Ratio Detection Assay Kit (ab138881).
Comet assay
Alkaline comet assay was performed as described previously [41] . After the treatment, cells were collected and run in alkaline buffer for 20 min and analyzed with the Olympus IX51 fluorescence microscope.
